Antimicrobial resistance patterns among aerobic Gram-negative bacilli isolated from patients in intensive care units: results of a multicenter study in Russia  by Stratchounski, Leonid S. et al.
ORIGINAL ARTICLE 
Antimicrobial resistance patterns among aerobic 
Gram-negative bacilli isolated from patients in 
intensive care units: results of a multicenter study in 
Russia 
Clin Microbiol Infect 1998; 4: 497-507 
Leonid S. Stratchounskil and the Russian NPRS Study Group," Roman S. Kozlov', 
Galina K. Rechedko', Olga U. Stetsioukl and Elena I? Chavrikova' 
'Department of Clinical Pharmacology and Antimicrobial Chemotherapy, State Medical Academy, 
and 'Clinical Research Organization, InnoPharm Ltd, Smolensk, Russian Federation 
Objective: To determine the antimicrobial resistance patterns among aerobic Gram-negative bacilli isolated from 
patients in intensive care units (ICUs) in different parts of Russia. 
Methods: During 1995-96,lO Russian hospitals from different geographic areas were asked t o  submit 100 consecutive 
Gram-negative isolates from patients with ICU-acquired infections. Minimal inhibitory concentrations (MICs) of 12 
antimicrobials were determined by Etest and results were interpreted according to  National Committee for Clinical 
Laboratory Standards (NCCLS) guidelines. 
Results: In total, 1005 non-duplicate strains were obtained from 863 patients. The most common species were 
Pseudomonas aeruginosa (28.8%), Escherichia coli (21.4%), Klebsiella pneumoniae (16.7%), Proteus mirabilis (9.7%), 
Enterobacter spp. (8.2%) and Acinetobacter spp. (7.7%). High levels of resistance were seen to  second- and third- 
generation cephalosporins, ureidopenicillins, p-lactam@-lactamase inhibitor combinations and gentamicin. The most 
active agents were imipenem (no resistance in  Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter 
spp. and Acinetobacter spp., 7% resistance in Pseudomonas aeruginosa), amikacin (7% resistance in Pseudomonas 
aeruginosa and Acinetobacter spp., 4% in Enterobacter spp., 1% in Escherichia coli and Proteus mirabilis, no resistance 
in Klebsiella pneumoniae) and ciprofloxacin (15% resistance in Pseudomonas aeruginosa, 5% in Enterobacter spp. and 
Proteus mirabilis, 2% in Klebsiella pneumoniae, 1% in Escherichia coli). 
Conclusions: Second- and third-generation cephalosporins, ureidopenicillins, P-lactam/P-Iactamase inhibitor combina- 
tions and gentamicin cannot be considered as reliable drugs for empirical monotherapy for aerobic Gram-negative 
infections in ICUs in Russia. 
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INTRODUCTION 
Nosocomial infections are important problems in 
hospitals. In spite of the advances in infection control 
measures, the mortality morbidity and cost of such 
infections remain extremely high. In a recent European 
prevalence study it was shown that intensive care unit 
(1CU)-acquired infections developed in 20.6% of all 
patients admitted [l]. The frequency of such infections 
varies significantly not only between countries, but 
also between different hospitals. There is an obvious 
necessity to know not only global trends in epidemio- 
l o g  of hospital infections but also the local situation. 
Monitoring of antimicrobial resistance is most 
important in ICUs, where infection rates and con- 
sumption of antimicrobials are significantly higher than 
in other wards. This practice also helps in optimization 
of empirical antimicrobial therapy, decreasing pre- 
scription of non-rational regimens of therapy, and 
increasing cost-effectiveness of treatment. 
The aim of this study was to determine the profile 
of antimicrobial resistance among aerobic Gram-negative 
bacilli isolated from patients with ICU-acquired in- 
fections in different parts of Russia. 
MATERIALS AND METHODS 
Study design 
Between September 1995 and May 1996, 10 centers 
in different parts of Russia (Figure l),  including 
the North-West European Region (Moscow, Saint 
Petersburg, Smolensk, Nizniy Novgorod), the South 
European Region (Krasnodar), the Central European 
Region (Kazan), Ural (Ekaterinburg), and Siberia 
(Novosibirsk, Krasnoyarsk), were asked to subniit a 
minimum of 100 consecutive aerobic Gram-negative 
isolates from patients with ICU-acquired infections. 
The cultures were performed on the basis of clinical 
indications. Only non-duplicate isolates were included 
in this study. All microorganisms were identified to 
species level. 
Processing of the strains 
Following isolation, identification and susceptibility 
testing, isolates were sent to the central laboratory in 
Smolensk on 0.7% nutrient agar slants. 
At least 20%) of strains were re-identified by API 
20E and API 20NE (BioMerieux, La Balme les Grottes, 
France). When more than 10% of discrepancies were 
observed, re-identification was performed for all sub- 
mitted isolates. 
All isolates were stored at  -70°C as a heavy 
wspension in trypticase soy broth with added glycerol 
(10% v/v). 
Susceptibility testing 
Minimal inhibitory concentrations (MICs) of 12 
antimicrobials were determined by Etest (AB Biodisk, 
Solna, Sweden). Interpretation of the results was 
performed according to National Committee for 
a 
RUS: 
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Figure 1 Geographic distribution of the centers included in this study. 
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Clinical Laboratory Standards (NCCLS) guidelines 
(1995). Validation of the procedures was by the 
determination of the MICs for Pseudomonas aeruginosa 
ATCC 27853 and Escherichia coli ATCC 35218. Test 
results were accepted only if the control strains' MICs 
were within performance range. As an additional 
quality control procedure, susceptibility testing of 20% 
of all strains was performed in the Research and 
Development Laboratory of AB Biodisk. 
The following antimicrobials were tested: piper- 
acillin, amoxycillin/clavulanate, piperacillin/tazobactam, 
cefuroxime, ceftriaxone, cefotaxime, ceftazidime, 
imipenem, gentamicin, amikacin, ciprofloxacin and 
trimethoprim/sulfamethoxazole. 
Data management 
Data management and statistical analysis was performed 
with SAS 6.11 (SAS Institute, USA). 
RESULTS 
Microorganisms 
During the study period, 1005 non-duplicate con- 
secutive strains from 863 patients were received 
and evaluated. The most common species, in order 
of frequency, were Pseudomonas aeruginosa (28.8%), 
Escherichia coli (21.4%), Klebsiella pneumoniae (16.7%), 
Proteus mirabilis (9.7%), Enterobacter spp. (8.2%) and 
Acinetobacter spp. (7.7%), representing 92.5% of all 
isolates. The remaining isolates included Citrobacter 
spp. (1.6%), Motgunella movganii (1.0%), Proteus vulgaris 
(1 .O%), Serratia marcescens (0.9%), Stenotrophomonas 
maltophilia (0.9%), and other Gram-negative bacilli 
The most common isolates submitted by centers 
are shown in Table 1. Escherichia coli was the most 
prevalent species in Saint Petersburg and Krasnoyarsk, 
Acinetobacter spp. in Ekaterinburg, and Enterobacter spp. 
in Moscow-2. 
(2. 1 %) . 
Body sites 
The body sites yielding specimens are presented in 
Figure 2. Among the wound isolates the most common 
microorganisms were Pseudomonas aeruginosa (38.2%), 
Escherichia coli (19.4%) and Pvoteus mirabilis (14.2%), 
from the respiratory tract Pseudomonas aeruginosa (37.4%), 
Klebsiellapneumoniae (23.1%) and Escherichia coli (13.2%), 
from the urinary tract Escherichia coli (33.1%), Pseudo- 
rnonas aeruginosa (1 8.0%) and Klebsiella pneumoniae 
(14.4%), and from the gastrointestinal tract Escherichia 
coli (32.1%), Klebsiella pneumoniae (19.5%), and Entero- 
bacter cloacae (18.9%). Klebsiella pneumoniae (45.7%), 
A. baumanii (17.4%) and Pseudomonas aeruginosa (15.2%) 
were the common species isolated from blood. 
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Figure 2 Distribution of body site samples. 
Administration of antimicrobials 
A total of 854 patients (99.0%) were receiving anti- 
microbials on the day samples were taken. Amino- 
glycosides were the most frequently administered 
(35.3% of total prescriptions), and gentamicin was the 
most commonly administered antibiotic (27.3% of total 
prescriptions), followed by third-generation cephalo- 
sporins (13.2%) and ampicillin (11.5%). Overall, 312 
patients (36.2%) were given more than one anti- 
inicrobial agent. 
Comparison of activity 
There were no major discrepancies between results 
obtained in Russia and those in the Research and 
Llevelopment Laboratory of AB Biodisk in Sweden. 
Summariey of MICsos, MICWS, MIC ranges and 
levels of resistance for the most common isolates are 
presented in Table 2. 
P-Lactams 
The most active p-lactani antibiotic against Pseudo- 
rr~oms nerr@nosa was imipenem (7% of resistance), 
followed closely by ceftazidime (1 1%). Inlipenem was 
‘dso the most active 8-lactani against Esclzerirliia 
roli, followed by third-generation cephalosporins 
(ceftazidime, ceftriaxone and cefotaxirne). Against 
Klehsiella pneumoniae,  imipenem showed the highest 
activity among the p-lactanis tested, followed by third- 
generation cephalosporins. Imipenem possessed the 
highest activity against Pvoteirs mivahilis, Enteroharter spp. 
and Acinetohactev spp. We observed quite low activity of 
piperacillin and piperacillin/tazobactam against both 
enterobacteria and non-fernienters. 
Arninoglycosides 
Aniikacin was significantly more active than gentamicin 
against all tested microorganisms. The resistance rates 
to amikacin varied from 00/1 in Klehsiella pnecrnzoniae to 
7% in Pseudomonas aeruginosa and Acinetohacter spp., 
compared with the resistance rates to gentamicin of 
58% in Klehsiella pneurnoniae, 75% in Pseudomoms 
aeruginosa and 91% in Acirietohacter spp. 
Fluoroquinolones 
Ciprofloxacin was selected as the most active drug 
among the currently available fluoroquinolones. I t  
showed good activity against enterobacteria (1-5% 
resistant), but was significantly less active against non- 
fermenters (1 5% resistance in Pseudormnas aercrgirzorn 
and 53% resistance in Acinetohacrer spp.). 
Comparison of resistance patterns between the centers 
Pseudomonas aeruginosa (Figure 3) 
The resistance of Pseudornorzas aeruginosn to piperacillin 
ranged from 10% in Saint Petersburg to 7Y% in 
Smolensk. A similar tendency has been observed with 
the activities of other antimicrobials. The resistance to 
ceftazidime was lowest in Ekaterinburg and Krasnodar 
Table 2 MICsos (mg/L), MICgos (mg/L), MIC ranges (mg/L) and resistance (oh) to tested antimicrobials for the most common bacterial species 
Antimicrobials 
Piperacillin Piperacilldtazobactam Amoxycillin/clavulanate Cefuroxime 
MICjo MICso MIC range R MICjo M I C ~ O  MIC range R MIC50 MIC911 MIC range R MICso MICso MIC range R 
Microorganism (mg/L) (mg/L) (rng/L) (%A) (mg/L) (nig/L) (tng/L) (“A) (mg/L) (mg/L) (mg/L) (“A) (mg/L) (mg/L) (mg/L) (“A) 
- - - - - - -  Pseudoinonas aeruginosa (n=289) 64 >256 2 to 2256 50 32 >256 1 to >2S6 41 - 
Esrlirrirkia roli (n=215) 4 >256 1 to >256 44 2 32 1 to >256 11  4 16 0.25-128 27 4 16 1-128 19 
Kl~bsi~llapnenmoriiar (w=168) >256 >256 4 to >256 85 16 >256 2 t o > 2 5 6  51 8 32 0.25-128 52 8 128 1-128 52 
Proteus mirabilis (n=97) 64 >256 1 t o > 2 5 6  59 1 2256 1 to >256 22 4 64 0.5-128 20 2 128 0.25-128 32 
Enrrrohart~r spp. (n =82) 2256 >256 2 to >256 70 >256 >256 1 to >256 63 64 128 0.5-128 88 128 128 2-128 82 
Arinc~obatter spp. (n =77) >256 >256 2 to >256 88 >256 >256 1 to >256 82 16 128 0.5-128 73 128 128 2-128 96 
Microorganism 
Pseudomonas aerugiriosa (n=289) 
Esrherichia toli (n=215) 
KIehsiella pncuinoniae (n = 168) 
Proteus mirabilis (n=97) 
Atinetobact~r spp. (n=77) 
El.p I r f ~  uclel spp. (G-SZ) 
Antimicrobial5 
Cefotaxime Ceftriaxone 
0.25 2 
2 128 
0.25 128 
64 128 
128 128 
0.25-128 6 
0.5-128 32 
0.25-128 20 
0.25-128 66 
0.5-128 88 
0.25 1 
2 128 
0.25 128 
6.: 12s 
128 128 
0.25-128 
0.25-128 
0.25-128 
0.25-128 
0.25-128 
R 
- 
5 
33 
17 
3 
94 
Ceftazidime Imipenem 
MICx MICqo MIC range K MICso MICgo MIC range R 
(mg/L) (mg/L) (mg/L) (“A) (mg/L) (mg/L) (mg/L) (%) 
4 8 0.25-128 11 2 4 0.5-64 7 
0.25 2 0.25-128 3 0.25 0.5 0.25-4 0 
2 128 0.25-128 26 0.25 0.5 0.13-4 0 
64 i28 0.25-128 56 0.5 2 u.i3-4 0 
0.25 1 0.25-16 1 1 4 0.13-4 0 
32 128 2-128 78 0.5 2 0.13-4 0 
Microorganism 
Gentamicin Amikacin Ciprofioxacin Co-trimoxazole 
Pseudomonas aewginosa (n=289) 32 128 0.5-128 75 4 16 1 to >256 7 0.5 2 0.06-32 15 - - -  - 
Estherirhia coli (n=215) 1 16 0.25-128 13 2 4 1-8 1 0.06 0.13 0.06-0.5 1 0.25 64 0.13-64 27 
Klebsielfn pneumonine (~1x168) 16 128 0.25-128 58 2 4 1-16 0 0.13 0.5 0.06-8 2 1 64 0.13-64 51 
Protrus inirabilis (n=97) 8 128 0.25-128 56 4 8 1-32 1 0.06 0.25 0.06-4 5 64 64 0.13-64 62 
Enrerobacter spp. (n=82) 2 128 0.5-128 42 2 4 1 to >256 4 0.13 0.5 0.06-8 5 0.25 64 0.13-64 12 
Arinetobacter spp. (n=77) 128 128 0.25-128 91 2 >256 1 to >2S6 7 2 32 0.06-32 53 64 64 0.13-64 88 
11, resistmce, xcording to NCCLS criteria. 
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Figure 3 Resistance ('XI) of Psrudornonas arqqinosn in  the 
study centers. 
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Figure 4 Resistance ("A) of Escherichia coli in the study centers. 
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Figure 5 Resistance ("A) of K. pneurnoniae in the study 
centers U 
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Figure 6 Resistance (%) of Proteeus mirabilir in the study 
centers. 
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(5%) and highest in Nizniy Novgorod (26%). Resist- 
ance to imipenem was comparatively low in all centers 
(0-1 1 'YO), excluding Kazan (29%). Gentamicin possessed 
relatively low activity against Pseudoinonas aeruginosa in 
all centers (from 40% resistance in Krasnoyarsk to 90% 
in Krasnodar). Ainikacin showed good activity in all 
centers, with a resistance range of 0-11%, excluding 
Nizniy Novgorod (18%) and Kazan (19%). Resistance 
to ciprofloxacin varied between 6%) and 42%. 
Escherichia coli 
As indicated in Figure 3, piperacillin showed quite poor 
activity against Esclierirlzia roli isolated in different 
centers, with the resistance ranging from 9% in 
Moscow-2 to 75% in  Smolensk. Piperacillin/tazo- 
bxtani was more active not only than piperacillin, but 
also than co-anioxiclav. 
Kle bsiella pne urnonia e 
Generally, piperacillin, piperacillin/tazobactam and co- 
aiiioxiclav possessed the lowest activity against Klebriella 
pienrnoniae isolates, with ranges of resistance of 58- 
lOO'%, 17-89% and 25-94%, respectively (Figure 5). 
Another problem is a high level of resistance to third- 
generation cephalosporins (more than 30%) in Kazan, 
Novosibirsk, Smolensk and Krasnoyarsk. 
Proteus rnirabilis 
The resistance of Protens rnirabilis in different centers 
is presented in Figure 6 .  Piperacillin showed relatively 
poor activity in all centers, with the resistance ranging 
from 47?4 in Krasnodar to 91% in Smolensk. Piperacdld 
tazobactani and co-amoxiclav had similar activity, with 
a resistance range of 0-64%. 
DISCUSSION 
To our knowledge, this study is the first multicenter 
study of ICU-acquired infections to be carried out in 
Russia. The design of this study included the simul- 
taneous collection of clinical material in all parti- 
cipating centers; it thus excluded the influence of time 
factors on patterns and frequency of hospital infections. 
Also of importance was the use of an internationally 
approved susceptibility testing method. We would also 
like to emphasize that selection of tested antimicrobials 
Lvas based on the drugs available in Russian hospitals. 
We feel that these data will be of real value for 
physicians in different hospitals, especially in the choice 
of empirical therapy. 
We compared our results with studies in western 
Europe, analyzing data from studies froni Germany [ 2 ] ,  
Belgium 131, The Netherlands [4] and Sweden I51 
which had a similar design. All of these studies included 
several centers (16 in Belgium, 10 in Germany and 
Sweden and eight in The Netherlands) and were 
focused on ICUs. Moreover, the centers were asked 
to submit susceptibility testing data on at  least 100 
consecutive Gram-negative isolates. We found a rela- 
tively high level of resistance among all Prr~rdoinonas 
nevuxinosa isolates in Russian ICUs to piperacillin (50% 
versus 8.5% in Sweden, 12% in Germany, 15% in The 
Netherlands and 18% in Belgium), and gentaniicin 
(75% versus 6.8% in Sweden, 40% in Germany, 41x1 in 
The Netherlands and 48% in Belgium). Resistance 
rates to gentanllcin of Esclievicliin c-oli in this study were 
also significantly higher (13% versus 2% in Germany 
and 4% in both Belgium and The Netherlands). The 
differences in the resistance rates for the other anti- 
microbials were riot so marked. Similar trends of 
resistance were observed in Klehsiella pneurnoniae: the 
resistance to gentamicin was 38% in comparison 
with 3% in Germany and 10%1 in The Netherlands. 
Such high levels of resistance to gentamicin might be 
explained by its high consumption in both outpatient 
clinics and hospitals, even for therapy of community- 
acquired pneunionia. 
I n  our analysis, ceftazidime was selected as the 
representative thrd-generation cephalosporin for detec- 
tion of resistance in strains that are hyperproducers of 
type I chroniosoinal P-lactaniases or that carry plasmid- 
mediated extended-spectrum P-lactainases 161. The 
coniparison of our data with recently published NPSP 
[7] and NNIS ICU [8] data shows that the rate of 
resistance among our Klebsiclla pnernnonine strains 
was significantly higher (26.2%) versus 5.8% and 2.6%, 
respectively). The resistance rate among Enrrrohactcr 
spp. was also higher (.56.1%1 versus 32.0% and 39.6%1, 
respectively), but the resistance among our Psendornonar 
aer~i~qinosu isolates was slightly lower (1 0.7% versus 
14.2%1 and 13.2'%i, respectively). 
We would like to draw attention to the high level 
of resistance of nosocomial strains of Aiinetobacrer spp. 
One of the most troubling issues is the increase of 
resistance to ciprofloxacin (53%1), which has been 
widely used for the treatment of Grani-negative in- 
fections in Kussian hospitals in recent years. 
Another interesting fact is that the resistance to 
many antimicrobials in Enterobarrer spp. coexists with 
quite good activity of trimethoprim/sulfamethoxazole, 
which potentially can be used for the treatment of these 
infections. 
Coniparatively high levels of resistance to combina- 
tions of p-lactam and p-lactaniase inhibitors among all 
species in different hospitals considerably restrict their 
use in the treatment of nosocomial infections. 
I n  conclusion, we would like to mention an 
important point. During this study we created a team 
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which will work on the control of hospital infections 
and will, we hope, develop guidelines and protocols for 
the treatment of infections in hospitals in Russia. 
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